Is Pseudoprogression a good thing?
Some studies have found that pseudoprogression indicates a better outcome, though more studies are needed. While researchers work to learn more about what causes pseudoprogression and what it may mean for patients who experience it, communication between doctors and patients is critical.
What is Pseudoprogression in brain cancer?
What Is Pseudoprogression? Radiologically, pseudoprogression is defined as a new or enlarging area(s) of contrast agent enhancement occurring early after the end of radiotherapy (eg, within 3–4 months), in the absence of true tumor growth, which subsides or stabilizes without a change in therapy7 (Fig. 1).
What is Pseudoprogression in glioblastoma?
Pseudoprogression (PsP) is a transient magnetic resonance imaging (MRI) pattern mimicking tumor progression but not necessarily accompanied by clinical deterioration. It occurs most frequently during the first 3 months after radiation therapy and improvement will usually occur within a few weeks or months.
How long does pseudo progression Last?
Pseudoprogression seems to be associated with a high likelihood of 1-year survival compared to patients experiencing partial response, stable disease or progressive disease in a retrospective analysis conducted on various cancer type.
How do doctors know if immunotherapy is working?
In general, a positive response to immunotherapy is measured by a shrinking or stable tumor. Although treatment side effects such as inflammation may be a sign that immunotherapy is affecting the immune system in some way, the precise link between immunotherapy side effects and treatment success is unclear.
How is Pseudoprogression treated?
In patients with pseudoprogression that have worsening of their symptoms due to transient cerebral edema, a short course of corticosteroids is warranted. Corticosteroids inhibit the pro-inflammatory response associated with the transient demyelination seen in pseudoprogression.
What is anaplastic astrocytoma grade3?
Grade 3. Anaplastic Astrocytoma is considered a more malignant evolution of a previously lower grade astrocytoma, which has acquired more aggressive features, including a higher pace of growth and more invasion into the brain.
How is brain necrosis treated?
Methods: Although asymptomatic necrosis rarely needs treatment, brain necrosis resulting in neurologic change can be treated with steroids, surgery, bevacizumab and/or hyperbaric oxygen therapy.
Why does Pseudoprogression happen?
When solid tumors are treated with immunotherapy agents, pseudoprogression is the phenomenon in which an initial increase in tumor size occurs or new lesions appear, followed by a decrease in tumor burden; these changes can be confirmed by tumor biopsy or a continuous radiography scan14-17.
Is Pseudoprogression common?
The incidence of pseudoprogression reported in prior studies was less than 10% [11,14,15].
What is pseudoprogression of cancer?
Pseudoprogression of cancer, or the apparent worsening of a cancer when it’s actually improving, is a relatively new concept in cancer treatment. With the exception of a type of brain cancer, it wasn’t until the introduction of immunotherapy drugs such as checkpoint inhibitors that it became relatively common to see tumors increase in size on
What is a false positive pseudoprogression?
Pseudoprogression. It refers to the false positive finding of progression and enhancement of the lesion. It is considered a treatment effect due to tumor cell necrosis and subsequent edema formation and increased vascular permeability. (NCI Thesaurus)
How is pseudoprogression diagnosed and treated?
Currently, pseudoprogression is diagnosed using retrospective imaging data, which critically impedes the optimal application of immune checkpoint inhibitors because clinicians cannot accurately evaluate the treatment.
What is the role of pseudoprogression in immunotherapy for melanoma?
Pseudoprogression during immunotherapy was first characterized in a phase II trial that evaluated the efficacy of ipilimumab, an anti-CTLA-4 antibody, in advanced melanoma [9]. The authors described a patient who experienced initial increased size of tumor lesions followed by a delayed partial response.